Features Pricing Learn Reverse Splits Tracker Shelf & ATM Tracker Warrant Tracker PIPE Deal Tracker Weekly Report FAQ API Sign In →
32 /100
MEDIUM RISK
Score updated Aug 28, 2026

AQST — Aquestive Therapeutics, Inc. Dilution Risk Tracker

Track AQST dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track AQST — Get alerts when the score changes →

As of August 28, 2026, Aquestive Therapeutics, Inc. (AQST) has a DilutionWatch DilutionScore of 32/100, rated MEDIUM dilution risk. Aquestive Therapeutics, Inc. has a market capitalization of $504.31M, 125.51M shares outstanding, 181 institutional holders tracked. Stored dilution-related fields include 375.0K outstanding warrants.

This page includes automatically generated factual summaries from DilutionWatch data. It is not financial advice, not investment research, and not a recommendation. Do your own research. Read the full disclaimer and terms of service.

Score Breakdown

📋 Offering Ability
46
💰 Cash Runway
10
📊 Float Risk
7
⚠️ Warrant Exposure
15
🔄 Convertible Debt
40

Dilution Forecast

☀️
Clear
No significant dilution signals
model est. 0%
No significant dilution signals detected for AQST.
🔔 Track AQST — Get forecast alerts →

Market Data

Market Cap$504.31M
Shares Outstanding125.51M
Float114.54M
Cash$98.49M
Debt$55.03M
Short InterestN/A

Institutional Holdings

QoQ: ↑ 2.4% shares (2026Q1 vs prior)
181 institutional holders · 79.04M shares
#1 Bratton Capital Management, L.P. 9.81M shares
#2 BlackRock, Inc. 7.51M shares
#3 RTW INVESTMENTS, LP 7.43M shares
+ 17 more holders Sign up free to view →

Institutional holder totals are aggregated from ownership filings and may use a different share basis or reporting date than public float. They are not a reconciliation against tradeable float.

Short Interest

Short Interest18.05M
Days to Cover8.9
% of Float15.8%
FINRA data as of Jul 31, 2026

Recent SEC Activity

xbrl XBRL WARRANT 2026-03-03
3 FORM3 2026-04-10
4 INSIDER TRANSACTION 2026-03-11
4 INSIDER TRANSACTION 2026-03-11
4 INSIDER TRANSACTION 2026-03-11
Full SEC filing analysis available with free account

Recent News

No recent news

Factual AQST Dilution Snapshot

Aquestive Therapeutics, Inc. (AQST) has a DilutionScore of 32/100, rated Medium dilution risk. Score date: August 28, 2026.

This automatically generated snapshot is assembled from stored DilutionWatch data fields and may contain data-source errors or omissions. It is not financial advice, not investment research, and not a recommendation. Do your own research and review the full disclaimer and terms of service.

Track AQST Dilution Risk in Real-Time
Get instant alerts when SEC filings impact dilution risk. Free tier available.
Start Tracking AQST — Free
Real-time SEC alerts DilutionScore™ tracking No credit card required

Related Stocks — MEDIUM Risk

Other MEDIUM dilution risk stocks tracked by DilutionWatch with similar profiles:

→ Biotech / Pharma sector dilution risk overview

Browse all 8,024+ tracked stocks →

📖 Dilution Education
→ Complete Dilution Guide for Retail Investors → Anti-Dilution Provisions Explained → Stock Dilution Red Flags to Watch → Understanding Shelf Registrations
More Research for AQST
AQST FDA Catalyst Timeline & Biotech Grade — BiotechSigns

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.